{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046124","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.774179+00:00","generated_at":"2026-05-22T04:17:29.579773+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M","bullets":["Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.","Net loss $11.3M vs $5.7M; operating loss $10.5M (prior-year included $7.6M asset sale gain).","Cash $42.8M; reiterates FY2025 revenue guidance $85-88M (23-27% growth), opEx flat YoY.","Full U.S. launch of larger OviTex PRS for plastic/reconstructive surgery commenced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046124","json":"https://secwatch.observer/filing/0001104659-25-046124.json","markdown":"https://secwatch.observer/filing/0001104659-25-046124.md","text":"https://secwatch.observer/filing/0001104659-25-046124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925046124/0001104659-25-046124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925046124/tm2514412d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:17:29.579773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}